Macquarie Group Ltd. lessened its holdings in Boston Scientific Corporation (NYSE:BSX) by 1.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 696,465 shares of the medical equipment provider’s stock after selling 7,191 shares during the quarter. Macquarie Group Ltd. owned about 0.05% of Boston Scientific Corporation worth $19,305,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of BSX. Los Angeles Capital Management & Equity Research Inc. acquired a new position in Boston Scientific Corporation in the 1st quarter worth approximately $215,000. Dynamic Technology Lab Private Ltd acquired a new position in Boston Scientific Corporation in the 1st quarter worth approximately $231,000. Teachers Advisors LLC increased its holdings in Boston Scientific Corporation by 2.8% in the 1st quarter. Teachers Advisors LLC now owns 6,144,846 shares of the medical equipment provider’s stock worth $152,822,000 after buying an additional 169,010 shares during the period. Sector Gamma AS increased its holdings in Boston Scientific Corporation by 13.4% in the 1st quarter. Sector Gamma AS now owns 1,423,880 shares of the medical equipment provider’s stock worth $35,412,000 after buying an additional 168,300 shares during the period. Finally, PNC Financial Services Group Inc. increased its holdings in Boston Scientific Corporation by 11.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 64,507 shares of the medical equipment provider’s stock worth $1,604,000 after buying an additional 6,767 shares during the period. Institutional investors own 90.44% of the company’s stock.

In other news, EVP Michael P. Phalen sold 15,500 shares of the company’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $27.13, for a total value of $420,515.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Supratim Bose sold 347,137 shares of the company’s stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $29.12, for a total value of $10,108,629.44. The disclosure for this sale can be found here. Insiders sold 531,297 shares of company stock worth $15,144,095 in the last three months. 0.74% of the stock is owned by corporate insiders.

Several brokerages recently weighed in on BSX. Needham & Company LLC reiterated a “buy” rating and issued a $32.00 price target on shares of Boston Scientific Corporation in a report on Tuesday, October 3rd. BMO Capital Markets reiterated a “buy” rating and issued a $30.00 price target on shares of Boston Scientific Corporation in a report on Friday. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $34.00 price target on shares of Boston Scientific Corporation in a report on Monday, October 2nd. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Boston Scientific Corporation in a report on Wednesday, August 9th. Finally, J P Morgan Chase & Co reiterated an “overweight” rating and issued a $31.00 price target (up previously from $27.00) on shares of Boston Scientific Corporation in a report on Wednesday, June 28th. One research analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Boston Scientific Corporation presently has an average rating of “Buy” and a consensus price target of $30.13.

Boston Scientific Corporation (NYSE:BSX) last posted its earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.01. The company had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. Boston Scientific Corporation’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.27 earnings per share.

ILLEGAL ACTIVITY WARNING: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/10/13/macquarie-group-ltd-cuts-position-in-boston-scientific-corporation-bsx.html.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Stock Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related stocks with our FREE daily email newsletter.